Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG | Grabenstrasse 11a, 8952 Schlieren, Switzerland
Zurich-Schlieren, Switzerland, July 1st, 2021. TOPADUR Pharma AG, a biopharmaceutical start-up company today is pleased to announce the submission of an application to the European Medicines Agency (EMA) to receive Orphan Drug Designation (ODD) status for its lead product TOP-N53 to treat digital ulcers in patients with systemic sclerosis.
“The submission of our ODD represents a major milestone for the Company and it brings significant benefits to the development process of TOP-N53,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “We believe that TOP-N53 has significant potential to provide a valuable treatment option for digital ulcers in patients afflicted by systemic sclerosis, a disabling condition.”
The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.
Read moreA Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.
Read moreThe shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.
Read more
